SCHEMBL10198977

SCHEMBL10198977

[C-]#[N+]c1cnc(Cl)nc1NC1CC(C)(C)N(C)C(C)(C)C1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.38
KMT2A Q03164 1/20 0.36
RET P07949 3/20 0.34
KIF5B P33176 3/20 0.34
KDR P35968 3/20 0.34
ETV6 P41212 3/20 0.34
KCNH2 Q12809 3/20 0.34
CCDC6 Q16204 3/20 0.34
FLT3 P36888 1/20 0.33
TYRO3 Q06418 1/20 0.33
MERTK Q12866 1/20 0.33
GAS6 Q14393 1/20 0.33
CYP3A4 P08684 1/20 0.33
SCN9A Q15858 1/20 0.33
PRKCQ Q04759 1/20 0.33
MAPK14 Q16539 2/20 0.32
MAPK13 O15264 1/20 0.32
MAPK12 P53778 1/20 0.32
MAPK11 Q15759 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10198975 0.84 KMT2A (0.37) AXLKMT2AKCNH2
SCHEMBL431462 0.81 KMT2A (0.58) AXLKMT2ARETKIF5BKDR
Hydrochloric Acid SCHEMBL430133 0.80 KMT2A (0.57) AXLKMT2ARETKIF5BKDR
SCHEMBL431181 0.78 CSNK1A1 (0.39) AXLKMT2AFLT3TYRO3MERTK
SCHEMBL10198971 0.76 FLT3 (0.44) FLT3TYRO3MERTKGAS6
SCHEMBL13248971 0.71 SYK (0.46) FLT3
SCHEMBL21385326 0.70 CYP3A4 (0.36) FLT3TYRO3MERTKGAS6CYP3A4
SCHEMBL10802588 0.68 PDE4A (0.46) CYP3A4SCN9AMAPK14MAPK13MAPK12
SCHEMBL1741047 0.65 PRKCQ (0.46) KMT2ARETKIF5BKDRETV6
SCHEMBL14545564 0.64 CNR1 (0.42) RETKIF5BKDRETV6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732070-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
US-20170152246-A1 Protein Kinase C Inhibitors and Uses Thereof MIDCAP FINANCIAL TRUST 2017-06-01 US disclosed
US-9181222-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-11-10 US disclosed
US-20140329842-A1 Protein Kinase C Inhibitors and Uses Thereof RIGEL PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-8710223-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2014-04-29 US disclosed
US-20120022092-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2012-01-26 US disclosed
US-20110130415-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329842-A1 Protein Kinase C Inhibitors and Uses Thereof PRKCH, PRKCA, PRKCB AXL 3793/4885KMT2A 3505/4885RET 621/4885
US-20110130415-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB AXL 3793/4885KMT2A 3505/4885RET 621/4885
US-20120022092-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB AXL 3793/4885KMT2A 3505/4885RET 621/4885
US-20170152246-A1 Protein Kinase C Inhibitors and Uses Thereof PRKCH, PRKCA, PRKCB AXL 3793/4885KMT2A 3505/4885RET 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.